2 months ago
9
CORRECTION - Financial agenda for 2025
Villepinte, 13 janvier 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025.
| Publications calendar |
|
|
|
|
|
|
|
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, in United States and Israël. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €786 million in revenue in 2023.
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
Contacts:
Guerbet
Jérôme Estampes, Chief Financial Officer + 33 1 45 91 50 00 / [email protected]
Christine Allard, Head of Public Affairs and Communications: +33 6 30 11 57 82 / [email protected]
Seitosei.Actifin
Marianne Py, Financial Communication + 33 1 80 48 25 31 / [email protected]
Jennifer Jullia, Press +33 1 56 88 11 19 / [email protected]
Attachment
